Questionnaire

1. T2DM patients experience an up to ___% increased risk of cardiovascular-related death:

2. CVOT assessment of new glucose-lowering drugs must include a 3P-MACE including ________ prior to registration:

3. Regulations state that if for the risk of MACE, the upper limit of the 95% confidence interval of the estimated risk is ___, the drug cannot be approved:

4. Of the DPP-4 inhibitors, which is/are associated with increased risk of hospitalisation for HF?

5. Which statement is incorrect? Mechanisms through which GLP-1 RAs affect glucose control include:

6. Of the GLP-1 RAs, liraglutide, semaglutide and exenatide are the preferred agents for reduction of ASCVD risk:

7. GLP-1 RAs should be avoided in patients with a history of:

8. All SGLT-2 inhibitors have demonstrated benefit for MACE in T2DM patients with HF and CKD:

9. Which of these SGLT-2 inhibitors is/are preferred for use in the T2DM patient with ASCVD?

10. Which statement is incorrect? Early results of some studies of combination therapy with SGLT-2 inhibitors and GLP-1 RAs have shown positive complementary effects on: